All In MedTech

Device Trial Radar · NCT00598663

SWITCH - Sensing With Insulin Pump Therapy to Control HbA1c

Randomized, Cross Over, Controlled, Multi-centric Study to Assess Whether Type 1 Diabetic Patients in Sub-optimal Glycemic Control Can Improve Using the Continuous Glucose Values of the MiniMed Paradigm REAL-Time Insulin Pump System Versus the MiniMed Paradigm Insulin Pump

Last checked: Nov 20, 2026Latest source record: Sep 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 153 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

153

Actual

Start

Jan 2008

Primary completion

Jul 2010

Study completion Jul 2010

Sponsor

Lead sponsor
Medtronic MiniMed, Inc.Public (MDT)
Sponsor type
Industry
First posted
Jan 22, 2008

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 6 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate whether the patients with Type 1 diabetes mellitus in sub-optimal glycemic control can achieve better glycemic control by using the Medtronic MiniMed Paradigm® REAL-Time Pump System with continuous glucose monitoring versus the Medtronic MiniMed Paradigm® REAL-Time Pump alone with Self Monitoring Blood Glucose (SMBG).Our null hypothesis is there is a 0% reduction in HbA1c from baseline compared to control group, after 6 months of treatment.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

  • insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System)Device

    6 months of pump plus continuous glucose sensing in conjunction to SMBG

  • insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)Device

    insulin pump with smbg to be worn for 6 months. 15 days in each 6 week period blinded continuous glucose sensing will be conducted.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HbA1c at 6 MonthTime frame: 6 months

Locations

8 sites in 7 countries. Site status is shown where the registry gives one.

  • Hospital Hietzing

    Vienna, Austria

  • Steno Diabetes Center

    Copenhagen, Denmark

  • Glostrup Hospital

    Glostrup Municipality, Denmark

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.